Reviewed by Dr. Rasha Ringa, Founder & General Manager, PKCS. Last reviewed: April 2026.
Iraq’s pharmaceutical regulatory framework rests on three institutions that work together: the Iraqi Ministry of Health (MOH) as the apex authority, the Iraqi Drug Regulatory Authority (IDRA) as the technical reviewer, and KIMADIA as the public-sector procurement arm. For a comprehensive walk-through of the registration process — timelines, dossier requirements, KIMADIA tenders, and common rejection reasons — see our pillar guide on Drug Registration in Iraq.
Key Regulatory Bodies
The Iraqi Ministry of Health serves as the primary regulatory authority for pharmaceutical products. Companies seeking to register medicines in Iraq must work through established channels that include product dossier submission, technical review, and authority communication.
Registration Pathways
Pharmaceutical companies looking to enter the Iraqi market must prepare comprehensive regulatory dossiers. The submission process requires documentation aligned with Common Technical Document (CTD) format, including quality, safety, and efficacy data.
Post-Marketing Requirements
Once a product is registered, companies are expected to maintain compliance with post-marketing obligations. These include pharmacovigilance reporting, periodic safety updates, and adherence to labeling requirements.
Working with a Local Representative
International companies entering the Iraqi market typically benefit from working with a local authorized representative who understands the regulatory landscape. A qualified representative can coordinate with the Ministry of Health, manage submissions, and support ongoing compliance activities.
At PKCS, we support companies in understanding and navigating these regulatory requirements through our regulatory affairs and authorized local representative services. Get in touch to learn how we can help.
Related resources
- Pillar guide: Drug Registration in Iraq — The complete 2026 guide — MOH, IDRA, KIMADIA, dossier requirements, timelines.
- PKCS Regulatory Affairs — Dossier preparation, submission, and lifecycle management.
- Local Pharmaceutical Representative — Local agent and MA holder representation for foreign manufacturers.
- Pharmacovigilance Services — PV system implementation and QPPV across MENA.
Talk to PKCS about your regulatory pathway
PKCS works with pharmaceutical, biotechnology, and medical device companies entering or expanding across Iraq, the UAE, Saudi Arabia, and the wider GCC. Get in touch for a confidential discussion.